6/26/2025

The AMG GW&K Small/Mid Cap Core Fund returned -8.17% for the first quarter of 2025, compared with -7.50% for its benchmark, the Russell 2500 Index.

Source: SeekingAlpha

6/25/2025

Source: SeekingAlpha

6/25/2025

The Victory RS Small Cap Growth Fund (Class A Shares, without sales charge) returned -16.29% for the three months ended March 31, 2025, underperforming the Russell 2000® Growth Index.

Source: SeekingAlpha

6/18/2025

Insmed Inc. (NASDAQ:INSM) is one of the 10 best growth stocks to buy according to billionaires. On June 10, Mizuho analyst Graig Suvannavejh reaffirmed his Outperform rating on Insmed and raised the price target from $96 to $110. The revision follows the encouraging Phase 2b results for Treprostinil Palmitil Inhalation Powder (TPIP) in treating pulmonary arterial […]

Source: Yahoo

6/17/2025

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies.

Source: SeekingAlpha

6/17/2025

Insmed Incorporated (NASDAQ:INSM) is one of the 10 Hot Large Cap Stocks to Buy Now. Tiago Fauth, an analyst from Wells Fargo, maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) on June 11, raising the associated price target to $119 from $107. The analyst based the positive rating on the promising developments in the company’s […]

Source: Yahoo

6/17/2025

Insmed Incorporated (NASDAQ:INSM) is one of the 12 best healthcare stocks to buy now. On June 11, Goldman Sachs analyst Andrea Tan reiterated a ‘Buy’ rating on the stock and increased the price target to $112 from $100. The adjustment underscores the analyst’s confidence about the company’s long-term prospects. The Buy rating comes on the […]

Source: Yahoo

6/13/2025

Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results […]

Source: Yahoo

6/13/2025

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.

Source: Yahoo

6/12/2025

We recently published a list of These 10 Stocks Are Flying High. In this article, we are going to take a look at where Insmed Inc. (NASDAQ:INSM) stands against other best-performing stocks on Wednesday. Insmed jumped for a second day on Wednesday, adding 7.75 percent to close at $97.98 apiece following plans to raise $650 […]

Source: Yahoo

6/12/2025

We recently published a list of Investors Are Gobbling Up Shares of These 10 Firms. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other top-performing companies on Tuesday. Insmed Inc. soared by 28.65 percent on Tuesday to close at $90.93 apiece following positive results from the […]

Source: Yahoo

6/12/2025

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, a

Source: Yahoo

6/11/2025

Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment’s impending Phase 2 data for pulmonary arterial hypertension. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of […]

Source: Yahoo

6/11/2025

Insmed Inc: * INSMED ANNOUNCES PRICING OF $750 MILLION PUBLIC OFFERINGOFCOMMON STOCK * INSMED INC - PRICES PUBLIC OFFERING OF 7.8 MILLION SHARESAT$96.00 PER...

Source: Finnhub

6/11/2025

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $97.5 million of shares of common stock. All of the shares to be sold

Source: Yahoo

6/11/2025

Insmed Incorporated (NASDAQ:INSM) on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension. The study met its primary endpoint and all secondary efficacy endpoints. For the primary endpoint, the placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) was 35%, with a Least Squares (LS) mean ratio of 0.65. The placebo-adjusted improvement in six-min

Source: Yahoo

6/11/2025

Liquidia finally launched Yutrepia after years of legal battles, but faces entrenched competition from United Therapeutics' Tyvaso DPI. Read why LQDA is a Sell.

Source: SeekingAlpha

6/11/2025

INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.

Source: Yahoo

6/11/2025

United Therapeutics Corporation faces competition as Insmed's PAH data impresses. Click for my updated look at UTHR stock and why I remain bullish.

Source: SeekingAlpha

6/11/2025

Presenter SpeechUnknown Executive [Audio Gap] As you think about the profile that has now emerged on the back of this data, where do you see TPIP fitting into the treatment landscape?Presenter...

Source: Finnhub